ArticleNeurocritical care2026
Development and Validation of a Prognostic Model Integrating the Red Cell Distribution Width-to-Serum Calcium Ratio and N-terminal pro-B-type Natriuretic Peptide for Outcome Prediction after Moderate-to-Severe Traumatic Brain Injury.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTraumatic brain injury (TBI) is recognized as a significant global public health issue associated with high morbidity and mortality. This study aimed to overcome the limitations of traditional prognostic models (e.g., International Mission on Prognosis and Analysis of Clinical Trials, IMPACT) by evaluating the red cell distribution width-to-serum calcium ratio (RCR) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) to determine their prognostic value among patients with moderate-to-severe TBI.
methodsWe retrospectively analyzed 210 consecutive patients admitted to the Trauma Center and Department of Neurosurgery, First Affiliated Hospital of Soochow University (January 2023-January 2025). Demographic, clinical, laboratory, and radiological data were collected. The primary endpoint was 6‑month unfavorable outcome (Glasgow Outcome scale score < 4). Associations between biomarkers and outcome were estimated using multivariable logistic regression. Nonlinearity was examined with restricted cubic splines. Discrimination was compared using receiver operating characteristic curves.
resultsHigher RCR and NT‑proBNP were independently associated with unfavorable outcome [adjusted OR for RCR, 4.871; 95% CI 1.929-12.300; adjusted OR for ln(NT‑proBNP), 2.495; 95% CI 1.648-3.776; both p < 0.001]. Rates of unfavorable outcome rose across RCR tertiles (21.4%, 47.9%, and 63.8%; p < 0.001). Adding both biomarkers to the IMPACT model improved discrimination (AUC 0.924 vs. 0.874; p < 0.001).
conclusionsCombined assessment of RCR and NT-proBNP enhances early prognostic accuracy in moderate-to-severe TBI, supporting their potential role as accessible biomarkers for refined risk stratification and individualized management.
Indexed as
Identifiers
41709068What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.